Natural aldose reductase inhibitor: A potential therapeutic agent for non-alcoholic fatty liver disease.

Natural aldose reductase inhibitor: A potential therapeutic agent for non-alcoholic fatty liver disease.
Curr Drug Targets. 2019 Oct 07;:
Authors: Qiu L, Guo C
Abstract
Aldose reductase (AR) has been reported to be involved in the development of non-alcoholic fatty liver disease (NAFLD). Hepatic AR is induced under hyperglycemia condition and converts excess glucose to lipogenic fructose, which contributes in part to the accumulation of fat in the liver cells of diabetes rodents. In addition, the hyperglycemia-induced AR or nutrition-induced AR causes suppression of the transcriptional activity of peroxisome proliferator-activated receptor (PPAR) α and reduced lipolysis in the liver, which also contribute to the development of NAFLD. Moreover, AR induction in non-alcoholic steatohepatitis (NASH) may aggravate oxidative stress and the expression of inflammatory cytokines in the liver. Here, we summarize the knowledge on AR inhibitors of plant origin and review the effect of some plant-derived AR inhibitors on NAFLD/NASH in rodents. Natural AR inhibitors may improve NAFLD at least in part through attenuating oxidative stress and inflammatory cytokine expression. Some of the natural AR inhibitors have been reported to attenuate hepatic steatosis through the regulation of PPARα-mediated fatty acid oxidation. In this review, we propose that the natural AR inhibitors are potential therapeutic agents for NAFLD.
PMID: 31589122 [Pub...

Source: Current Drug Targets - October 6, 2019 Category: Drugs & Pharmacology Authors: Qiu L, Guo C Tags: Curr Drug Targets Source Type: research